News

Panel supports lower doses of novel insomnia drug


 

FROM AN FDA ADVISORY PANEL MEETING

Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Zolpidem Linked to Higher Inpatient Fall Rates
MDedge Psychiatry
REM sleep problems predict Parkinson's, Lewy body dementia
MDedge Psychiatry
Older patients report frequent insomnia, sleep treatment use
MDedge Psychiatry
Preclinical brain amyloid deposition linked to poor sleep
MDedge Psychiatry
Sleep terrors in adults: How to help control this potentially dangerous condition
MDedge Psychiatry
Antipsychotics for nonpsychotic illness
MDedge Psychiatry
The ABCDEs of obstructive sleep apnea
MDedge Psychiatry
Sleepless and paranoid
MDedge Psychiatry
Off-label use of antipsychotics
MDedge Psychiatry
Sleep disturbances in older adults
MDedge Psychiatry